| Literature DB >> 31287582 |
Matteo Cameli1, Eufemia Incampo1, Romina Navarri1, Giulia Elena Mandoli1, Carlotta Sciaccaluga1, Francesca Maria Righini1, Elisabetta Palmerini1, Nicolò Sisti1, Sergio Mondillo1, Stefano Lunghetti1.
Abstract
Heart failure (HF) represents a deadly epidemic that nowadays affects more than 2% of the general population, representing a major public health concern that implies a high economic burden for the health system. Levosimendan in HF patients is usually used for its inotropic and vasodilator effects that act without myocardial oxygen consumption, differently from other inotropic drugs. The symptoms and hemodynamic profile improve together with the myocardial function, and this can be demonstrated by an echocardiographic examination. Currently, the available data about the effects of levosimendan assessed by echocardiography are still lacking. This review discusses the role of echocardiography in the evaluation of therapeutic effects of levosimendan in HF.Entities:
Keywords: echocardiography; heart failure; levosimendan; therapeutic effects
Mesh:
Substances:
Year: 2019 PMID: 31287582 DOI: 10.1111/echo.14419
Source DB: PubMed Journal: Echocardiography ISSN: 0742-2822 Impact factor: 1.724